In a report released on October 4, Gregory Renza from RBC Capital maintained a Hold rating on MannKind (MNKD – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $4.07.
According to TipRanks, Renza is a 4-star analyst with an average return of 3.8% and a 38.73% success rate. Renza covers the Healthcare sector, focusing on stocks such as ACADIA Pharmaceuticals, Seagen, and Amgen.
Currently, the analyst consensus on MannKind is a Moderate Buy with an average price target of $6.67.
See the top stocks recommended by analysts >>
The company has a one-year high of $5.75 and a one-year low of $2.91. Currently, MannKind has an average volume of 2.69M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MannKind (MNKD) Company Description:
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
Read More on MNKD:
